National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

anti-PD-1 human monoclonal antibody MDX-1106
A fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity. Anti-PD-1 human monoclonal antibody MDX-1106 binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands PD-L1 and PD-L2, resulting in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and effector function through the suppression of P13k/Akt pathway activation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code names:MDX-1106
ONO-4538



Previous:anti-IL-13 humanized monoclonal antibody TNX-650, anti-IL-6 chimeric monoclonal antibody, anti-KIR monoclonal antibody 1-7F9, anti-myeloma cell surface antigen immunoconjugate BT-062, anti-p53 T-cell receptor-transduced peripheral blood lymphocytes
Next:anti-PD-1 monoclonal antibody CT-011, anti-PD-L1 monoclonal antibody MDX-1105, anti-PLGF monoclonal antibody TB-403, anti-PSCA fully human monoclonal antibody MK4721, anti-thymocyte globulin

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov